---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000021"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:52:12.885752+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# AEON Biopharma advances ABP-450 biosimilar program, secures $20M funding

## Summary
- Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference product for all therapeutic indications.
- Initiated primary analytical studies in Q4 2024; plans BPD Type 2a meeting with FDA in H2 2025.
- Closed $20M public offering in Jan 2025; ~89% of Series B warrants exercised as of March 21, 2025.
- No specific FY2024 financial results disclosed in the press release; focus on development and funding.

## SEC filing metadata
- accession: 0001837607-25-000021
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000021/0001837607-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000021/aeon-20250324x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000021
- JSON: https://secwatch.observer/filing/0001837607-25-000021.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.